Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates

OBJECTIVES: The availability of new β-lactam/β-lactamase inhibitors ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam have redefined contemporary treatment of Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) infections. We aimed to characterize and cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogers, Tara M, Kline, Ellen G, Griffith, Marissa P, Jones, Chelsea E, Rubio, Abigail M, Squires, Kevin M, Shields, Ryan K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035640/
https://www.ncbi.nlm.nih.gov/pubmed/36968951
http://dx.doi.org/10.1093/jacamr/dlad022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035640/
https://www.ncbi.nlm.nih.gov/pubmed/36968951
http://dx.doi.org/10.1093/jacamr/dlad022

Ejemplares similares